Nizatidine

Duodenal ulcer: continue treatment for four weeks (may be shortened if healing is confirmed earlier by endoscopy); if complete healing has not occurred after four weeks, continue for a further four weeks. Benign gastric ulcer: 300 mg daily in the evening for four or, if necessary, eight weeks — exclude the possibility of gastric cancer before treatment. Prevention of duodenal or benign gastric ulcer recurrence (prophylactic maintenance therapy): 150 mg daily in the evening. Gastro-oesophageal reflux disease: 150 mg twice daily up to 300 mg twice daily; therapy for up to 12 weeks is indicated for erosions, ulcerations and associated heartburn. Gastric and/or duodenal ulcer associated with concomitant NSAID use: 300 mg daily (either 300 mg at bedtime or 150 mg twice daily, morning and evening) for up to 8 weeks — most ulcers heal within 4 weeks and NSAIDs may be continued during treatment. Elderly: age does not significantly influence efficacy or safety and dosage modification is not normally required except in moderate to severe renal impairment (creatinine clearance less than 50 mL/min). Paediatric population: safety and efficacy in children have not been established, no data available.